{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:37:30Z","timestamp":1715953050200},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11239-014-1075-4","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T15:55:13Z","timestamp":1395935713000},"page":"423-429","source":"Crossref","is-referenced-by-count":17,"title":["PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease"],"prefix":"10.1007","volume":"38","author":[{"given":"G.","family":"Rosser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tricoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. N.","family":"Niespialowska-Steuden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kozarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"issue":"19","key":"1075_CR1","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jacc.2010.01.034","volume":"55","author":"JA Barrabes","year":"2010","unstructured":"Barrabes JA, Galian L (2010) Endogenous thrombolysis. J Am Col Cardiol 55(19):2116\u20132117","journal-title":"J Am Col Cardiol"},{"key":"1075_CR2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919\u2013933","journal-title":"J Am Coll Cardiol"},{"key":"1075_CR3","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jacc.2012.11.080","volume":"61","author":"DA Gorog","year":"2013","unstructured":"Gorog DA, Fuster V (2013) Platelet function tests in clinical cardiology. J Am Coll Cardiol 61:2115\u20132129","journal-title":"J Am Coll Cardiol"},{"key":"1075_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2009.10","volume":"6","author":"JM Sweeny","year":"2009","unstructured":"Sweeny JM, Gorog DA, Fuster V (2009) Antiplatelet drug \u201cresistance\u201d. Part 1. Mechanisms and clinical measurements. Nat Rev Cardiol 6:273\u2013282","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"1075_CR5","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","volume":"55","author":"S Saraf","year":"2010","unstructured":"Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA (2010) Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 55(19):2107\u20132115","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1075_CR6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehs300","volume":"34","author":"S Sharma","year":"2013","unstructured":"Sharma S, Farrington K, Kozarski R et al (2013) Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J 34(5):354\u2013363","journal-title":"Eur Heart J"},{"issue":"1","key":"1075_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000315494","volume":"37","author":"K Taomoto","year":"2010","unstructured":"Taomoto K, Ohnishi H, Kuga Y et al (2010) Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test. Pathophysiol Haemost Thromb 37(1):43\u201348","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"8","key":"1075_CR8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/09537100020027833","volume":"11","author":"S Nakajima","year":"2000","unstructured":"Nakajima S, Noguchi T, Taka T et al (2000) A global platelet test of thrombosis and thrombolysis detects a prothrombotic state in some patients with non-insulin dependent diabetes and in some patients with stroke. Platelets 11(8):459\u2013466","journal-title":"Platelets"},{"key":"1075_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399402004362","volume":"4","author":"PF Bodary","year":"2002","unstructured":"Bodary PF, Wickenheiser KJ, Eitzman DT (2002) Recent advances in under-standing endogenous fibrinolysis: implications for molecular-based treatment of vascular disorders. Expert Rev Mol Med 4:1\u201310","journal-title":"Expert Rev Mol Med"},{"key":"1075_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2004.05.004","volume":"114","author":"TH Taher","year":"2004","unstructured":"Taher TH, Stang L, Gordon PA et al (2004) Clopidogrel does not induce fibrinolysis in healthy subjects. Thromb Res 114:97\u2013100","journal-title":"Thromb Res"},{"key":"1075_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11239-006-6579-0","volume":"21","author":"IB Kovacs","year":"2006","unstructured":"Kovacs IB, Gorog DA, Yamamoto J (2006) Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis 21:221\u2013227","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"1075_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/hrt.2003.027110","volume":"91","author":"D Tousoulis","year":"2005","unstructured":"Tousoulis D, Antoniades C, Bosinakou E et al (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91(1):27\u201331","journal-title":"Heart"},{"issue":"5","key":"1075_CR13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1538-7836.2006.01882.x","volume":"4","author":"A Undas","year":"2006","unstructured":"Undas A, Celinska-L\u00f6wenhoff M, L\u00f6wenhoff T et al (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4(5):1029\u20131036","journal-title":"J Thromb Haemost"},{"issue":"24","key":"1075_CR14","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jacc.2009.11.095","volume":"55","author":"DA Gorog","year":"2010","unstructured":"Gorog DA (2010) Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 55(24):2701\u20132709","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1075_CR15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07853890600852898","volume":"38","author":"BN Bouma","year":"2006","unstructured":"Bouma BN, Mosnier LO (2006) Thrombin activatable fibrinolysis inhibitor (TAFI)\u2014how does thrombin regulate fibrinolysis? Ann Med 38(6):378\u2013388","journal-title":"Ann Med"},{"key":"1075_CR16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","volume":"373","author":"RC Becker","year":"2009","unstructured":"Becker RC, Moliterno DJ, Jennings LK et al (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919\u2013928","journal-title":"Lancet"},{"issue":"1","key":"1075_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366(1):20\u201333","journal-title":"N Engl J Med"},{"issue":"15","key":"1075_CR18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP et al (2012) TRA 2P\u2013TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404\u20131413","journal-title":"N Engl J Med"},{"key":"1075_CR19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001721-200301000-00007","volume":"14","author":"J Yamamoto","year":"2003","unstructured":"Yamamoto J, Yamashita T, Ikarugi H et al (2003) Gorog thrombosis test: a global in vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis 14:31\u201339","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1075_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2010.07.002","volume":"152","author":"DA Gorog","year":"2011","unstructured":"Gorog DA, Yamamoto J, Saraf S et al (2011) The first direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the \u201cJapanese paradox\u201d. Int J Cardiol 152:43\u201348","journal-title":"Int J Cardiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-014-1075-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-014-1075-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-014-1075-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:02:05Z","timestamp":1559386925000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-014-1075-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,28]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1007\/s11239-014-1075-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,28]]}}}